Drug Profile
Research programme: benzoylphenylurea sulfur analogues - Champions Oncology
Alternative Names: SG-410; SG-430Latest Information Update: 07 Apr 2011
Price :
$50
*
At a glance
- Originator Johns Hopkins University
- Developer Champions Oncology
- Class Organic sulfur compounds
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 04 Apr 2011 Champions Biotechnology is now called Champions Oncology
- 01 Apr 2011 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 03 Nov 2010 Champions Biotechnology receives Qualifying Therapeutics Discovery Project grant from the US Department of Health and Human Services for benzoylphenylurea sulfur analogues development in Cancer